Kabi Widens The Net With US Aflibercept Deal, As Amgen Biosimilar Hearing Nears
Deal With South Korea’s SamChunDang Pharm Includes South American Countries
Fresenius Kabi is to diversify its offering beyond immunology and oncology after putting pen to paper on a deal for a US biosimilar to Eylea, in the wake of Amgen’s surprise at-risk launch.
